1. Screening for MEN1-associated neoplasia
Screening for MEN1-associated neoplasia. Testing is targeted to individuals who either harbor the MEN1 gene or have a high probability of harboring the MEN1 gene (eg, first-degree relatives of affected kindred members). If genetic testing is available and the specific mutation has been confirmed, screening for endocrine neoplasia would be limited to those individuals harboring the defective gene. Screening for other pancreatic (eg, insulinomas) or pituitary tumors (eg, somatotroph adenomas) is based on the prevalence of the specific lesion in the affected kindred or the presence of signs or symptoms suggesting a particular lesion (IGF, insulin-like growth factor).
Source: Multiple Endocrine Neoplasia, Greenspan's Basic & Clinical Endocrinology, 10e
Citation: Gardner DG, Shoback D. Greenspan's Basic & Clinical Endocrinology, 10e; 2017 Available at: Accessed: November 15, 2017
Copyright © 2017 McGraw-Hill Education. All rights reserved